Authors: Shiloh M Martin Robert T O’Donnell David L Kukis Craig K Abbey Hayes McKnight Julie L Sutcliffe Joseph M Tuscano
Publish Date: 2008/10/24
Volume: 11, Issue: 2, Pages: 79-
Abstract
Mice bearing human nonHodgkin’s lymphoma NHL xenografts were injected IV IP or SQ with 64CuDOTAHB227 Xenograft targeting was evaluated by micro positron emission tomography microPET and confirmed by organ biodistribution studies Blood measurements of 64Cu were performed to determine the pharmacokinetics and clearance of 64CuDOTAHB22764CuDOTAHB227 demonstrated equivalent tumor targeting within 24–48 h regardless of the route of administration Organ biodistribution confirmed tumorspecific targeting Blood pharmacokinetics demonstrated that 64CuDOTAHB227 accessed the bloodstream after IP and SQ administration to a similar degree as IV administration albeit at a slower rateThese findings establish 64CuDOTAHB227 as a potential radioimmunotherapeutic and/or NHLspecific imaging agent These findings provide evidence that IP and SQ administration can achieve results equivalent to IV administration and may lead to more efficient reproducible treatment plans for antibodybased therapeutics
Keywords: